Needle Free Advantage Crossject's ZENEO autoinjector enables needle free intramuscular delivery on bare skin or through clothing, reducing training and administration barriers for emergency meds. This capability positions the company to target EMS providers, hospitals, schools, and caregiver networks with ZEPIZURE and other rescue therapies, expanding high value sales across urgent care settings.

Government Backing The company is advancing ZEPIZURE under a significant government program, with BARDA support underscoring regulatory progress and potential for large scale public procurement. This creates sales opportunities with government health agencies and disaster preparedness programs for emergency medications and platforms.

US Market Expansion Crossject USA Inc funding activity and active North American operations signal a focus on expanding distribution and partnerships in the United States. This presents opportunities to partner with US distributors, integrated delivery networks, and hospital systems for Zeneo based rescue meds and future products.

Rescue Pipeline Beyond ZEPIZURE Crossject is developing multiple rescue therapies including treatments for allergic shocks, adrenal insufficiency, opioid overdose, and asthma. A broadened pipeline increases addressable markets with EMS, urgent care, anesthesia, and specialty pharmacies, enabling cross sell and portfolio based deals with pharma collaborators and distributors.

Platform Licensing The Zeneo platform represents a versatile drug delivery technology with potential licensing or co development deals with pharma partners seeking needle free auto injectors. Strategic partnerships and licensing could accelerate adoption of the platform across additional therapies and markets, supported by existing partnerships and financing activity.